In esophageal cancer cells, PPARG activation by rosiglitazone led to suppressed proliferation and induced apoptosis through the inhibition of the Toll-like receptor 4 (TLR4)-dependent MAPK pathway [43]. Here, PPARG is linked to esophageal cancer.